Fountain of Youth Formulation Information & Administrative Coordination for Licensed U.S. Clinics
“Fountain of Youth,” sometimes shortened to FOY, is a nonstandard marketing name used for multi-peptide preparations. The name itself does not establish a standardized formulation, FDA approval, compounding eligibility, or clinical use.
This page refers to formulations described as containing GHK-Cu, Epitalon, BPC-157, and TB-500. Because products marketed under the same name may differ, clinics should review the actual component list and pharmacy documentation for the specific preparation under consideration.
Phoenix Meds Inc. supports licensed U.S. healthcare organizations with clinic verification, documentation organization, access to publicly available regulatory information, and administrative communication with independent licensed pharmacies.
Phoenix Meds is not a pharmacy, medical practice, manufacturer, prescriber, wholesaler, distributor, or dispensing entity.
What Licensed Clinics Should Know About “Fountain of Youth” Formulations
Current FDA and Compounding Status
FDA evaluates bulk drug substances used in compounding on a substance-by-substance basis.
In July 2026, FDA presented BPC-157-related, TB-500-related, and Epitalon-related bulk drug substances to the Pharmacy Compounding Advisory Committee as part of its evaluation for possible inclusion on the section 503A Bulks List. FDA’s briefing materials proposed that the evaluated free-base and acetate forms not be included on the list.
These proposals and advisory-committee proceedings should not be described as FDA approval, a product-specific ban, or a final regulatory determination for a multi-component preparation marketed as “Fountain of Youth.”
GHK-Cu is treated separately in FDA’s current compounding materials. GHK-Cu except for injectable routes is currently listed in 503A Category 1 among substances under evaluation. FDA has separately identified potential safety concerns for compounded injectable GHK-Cu, including potential immunogenicity associated with aggregation and peptide-related impurities, and has noted limited human safety information. FDA has announced plans for additional advisory-committee consideration of GHK-Cu before the end of February 2027.
The FDA materials reviewed for this page address the individual bulk drug substances. They do not establish FDA approval or a separate compounding status for the four-component formulation described on this page.
Compounded drugs are not FDA-approved, and FDA does not review them before marketing for safety, effectiveness, or quality in the same manner as FDA-approved drug products.
Why Component Identity Matters
A marketing name alone is not enough to determine what a preparation contains. For a professional review, clinics may need to consider:
- the complete ingredient list;
- the identity of each peptide or other component;
- the route and formulation;
- product labeling;
- storage information supplied with the preparation;
- the dispensing pharmacy; and
- supporting documentation associated with the specific preparation.
Changes in ingredients or formulation can materially change the regulatory questions that need to be considered.
Phoenix Meds can help organize available information so questions about the individual components can be directed to the appropriately licensed pharmacy or other responsible professional.
How Phoenix Meds Supports Licensed Clinics
Phoenix Meds provides administrative support for licensed U.S. healthcare organizations managing clinic-pharmacy communication.
For inquiries involving multi-component peptide formulations, our role may include clinic credential verification, organization of available formulation and pharmacy documentation, access to publicly available regulatory information, and administrative follow-up with independent licensed pharmacies.
Our role is administrative. Phoenix Meds does not determine whether a formulation may be compounded, prescribe treatment, select ingredients for a patient, certify product quality, or determine clinical appropriateness.
Clinical and pharmaceutical decisions remain with the licensed professionals and entities responsible for those activities.
Safety and Documentation Considerations
Combination preparations require careful attention to the identity and documentation of each component.
FDA’s evaluation of one substance does not establish the safety, effectiveness, or regulatory status of a multi-component blend containing that substance. The absence of a standardized formulation also means information about one product marketed under the “Fountain of Youth” name should not automatically be applied to another.
Phoenix Meds may help organize labeling, formulation information, pharmacy information, and supporting records made available during the administrative process.
We do not independently test or certify purity, potency, sterility, stability, authenticity, safety, effectiveness, or regulatory compliance.
FOY Administrative Coordination for Licensed Clinics
Phoenix Meds helps licensed U.S. healthcare organizations manage the administrative steps involved in reviewing FOY-related pharmacy inquiries, including clinic verification, documentation organization, and access to publicly available regulatory information. Our role is to help keep the process organized and reduce administrative back-and-forth between clinic teams and independent licensed pharmacies. An administrative inquiry is not a medication order and does not determine product availability, compounding eligibility, or clinical appropriateness.
Clinic Verification
Documentation Review
Phoenix Meds can help organize available component information, formulation details, pharmacy documentation, labeling, and relevant public regulatory information so the clinic can identify questions requiring further review.
Licensed Parties
Frequently Asked Questions
Is “Fountain of Youth” an FDA-approved drug product?
No. “Fountain of Youth” is a marketing-style name rather than the name of an FDA-approved drug product.
If the name is used for a compounded preparation, that compounded preparation is not FDA-approved.
Is there one standard Fountain of Youth formulation?
No standardized formulation should be assumed from the name alone.
This page discusses formulations described as containing GHK-Cu, Epitalon, BPC-157, and TB-500, but clinics should confirm the actual component list and documentation for the specific preparation they are reviewing.
Has FDA evaluated the Fountain of Youth combination itself?
The FDA materials reviewed for this page address GHK-Cu, BPC-157, TB-500, and Epitalon as individual bulk drug substances. We did not identify an FDA approval or separate FDA compounding determination for a four-component preparation marketed under the “Fountain of Youth” name.
FDA findings concerning an individual component should not be interpreted as approval, validation, or a regulatory determination for the combination as a whole.
What is the current FDA context for the individual components?
FDA reviewed BPC-157-related, TB-500-related, and Epitalon-related bulk drug substances during its July 2026 section 503A advisory-committee process and proposed that the evaluated forms not be included on the 503A Bulks List.
GHK-Cu is being considered separately, and FDA has published potential safety concerns relating specifically to injectable GHK-Cu.
Does Phoenix Meds verify the quality or safety of an FOY preparation?
No. Phoenix Meds does not independently test or certify purity, potency, sterility, stability, authenticity, quality, safety, or clinical suitability. We may help organize documentation made available by independent licensed entities.
What can Phoenix Meds help a licensed clinic with?
Phoenix Meds can support clinic credential verification, documentation organization, access to publicly available regulatory information, and administrative communication with independent licensed pharmacies.
Clinical, pharmaceutical, and regulatory determinations concerning a particular preparation remain with the appropriately licensed parties.
Important Notice
Phoenix Meds Inc. provides administrative coordination and documentation support for licensed U.S. healthcare organizations.
We are not a pharmacy, medical practice, manufacturer, wholesaler, distributor, prescriber, or dispensing entity.
Information on this page is intended for professional informational purposes. It is not medical advice, a prescribing recommendation, FDA approval, or a determination that a particular formulation is available, eligible for compounding, safe, effective, or clinically appropriate.
Regulatory Resources
- FDA — July 23–24, 2026 Pharmacy Compounding Advisory Committee Meeting
- FDA — Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks
- FDA — Bulk Drug Substances Nominated for Use in Compounding Under Section 503A
- FDA — Compounding and FDA: Questions and Answers
- FDA — Human Drug Compounding